ClinicalTrials.gg
RecruitingNCT05845372Updated Nov 5, 2026

Association of Prophylactic Use of Stress Ulcer Drugs and Clinical Outcomes in Patients With Acute Anterior Circulation Thrombectomy

An observational study in Acute Ischemic Stroke, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 19 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Nanfang Hospital, Southern Medical University · Observational

How we know

From the registry’s dates

  • Started May 2023; still recruiting 3 years 6 months later.
Updated Nov 5, 2026Now RecruitingSite recruiting status changed+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,592
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Ischemic Stroke by Nanfang Hospital, Southern Medical University — 12 open to participants now, 12 under way, 1 of them phase 3. Ischemic Stroke · Nanfang Hospital, Southern Medical University.

Started
2023
with 1 other
Observational
7 of 14
6 open now
Primary completion
2026-08
later than 5 of 11 live
Registered
8th of 14
by date

Among the 14 studies in Ischemic Stroke by Nanfang Hospital, Southern Medical University, this one is one of 2 that started in 2023, is one of 7 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 8th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

12 of the 14 studies in Ischemic Stroke by Nanfang Hospital, Southern Medical University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Ischemic Stroke by Nanfang Hospital, Southern Medical University, or all of them as a file.
02

Study summary

Ischemic stroke accounts for a relatively high proportion of strokes. In recent years, intravenous thrombolysis and endovascular therapy have significantly improved the revascularization rate in patients with large vessel occlusive cerebral infarction, but 20-50% of patients still experience ineffective revascularization. Therefore, postoperative monitoring and treatment of patients with large vessel occlusions is crucial for early recognition, management and prevention of complications. Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, and a previously proven incidence of stress ulcer bleeding after ischemic stroke. Stress ulcer bleeding after ischemic stroke has been shown to be closely associated with unfavorable outcomes, such as mortality. Current national and international guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for the prevention of stress ulcers, but rather should be considered in the context of the patient's risk factors for stress ulcers and discontinued after the patient initiates enteral nutrition. However, there is no evidence-based medical evidence to support the risk-benefit relationship of stress ulcer drug prophylaxis in patients with mechanical thrombectomy for acute anterior circulation large vessel occlusion.

Read the detailed description

Stress ulcer bleeding is a serious complication after acute ischemic stroke, with a prevalence of 1%-5%, of which only 0.5%-1% require blood transfusion or result in hypotension. Stress ulcer bleeding after ischemic stroke has been shown to be associated with poor outcomes, such as mortality, and basilar artery occlusion and middle cerebral artery cerebral infarction are independent risk factors for stress ulcer bleeding after acute ischemic stroke. Guidelines or consensus on the prevention of stress ulcers after acute ischemic stroke do not advocate the routine use of histamine receptor antagonists or proton pump inhibitors for stress ulcer prevention.

However, stress ulcer prophylaxis is initiated in most patients admitted to the neurological intensive care unit after mechanical embolization of acute anterior circulation large vessel occlusion. With advances such as diagnosis and early initiation of enteral nutrition, the rate of stress ulcer bleeding in patients with mechanical embolization of acute anterior circulation large vessel occlusion is significantly reduced. The relationship between the risk and benefit of SUP in patients undergoing mechanical embolization for acute anterior circulation large vessel occlusion is not yet supported by evidence-based medical evidence. Therefore, the purpose of this study was to investigate the correlation between pharmacological stress ulcer prophylaxis and clinical outcomes in patients undergoing mechanical thrombectomy for acute anterior circulation large vessel occlusion.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

Keywords

  • Acute Ischemic Stroke
  • Stress Ulcer Bleeding
  • Mechanical Thrombectomy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients who are treated with mechanical thrombectomy with acute anterior circulation large vessel occlusion. ≥18 years of age, within 24 hours of onset. Expected survival >3 months. NIHSS score ≥ 6 at onset of illness.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥18 years.
  2. Within 24 hours of onset. Meet the criteria for diagnosis of acute ischemic stroke in the "China Acute Ischemic Stroke Diagnosis and Treatment Guidelines 2018".
  3. Meet the indications for mechanical thrombectomy in the "Chinese Guidelines for Early Endovascular Interventions in Acute Ischemic Stroke 2022".
  4. Treated with mechanical thrombectomy.
  5. NIHSS score ≥ 6 at onset of illness.
  6. Sign an informed notice.

Exclusion criteria

Exclusion Criteria:

Allergy to drug ingredients. Women who are pregnant or breastfeeding. of less than 3 months due to other non-ischemic stroke diseases such as , severe liver or renal failure.

Have participated in other interventional clinical studies (affecting the outcome of this cohort study).

Participants who were judged by the investigator to be unsuitable for participation in this study.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,592 participants (estimated)
Patient registry
No

Groups and cohorts

  • Stress Ulcer Prophylaxis

    Subjects are on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.

  • Control Group

    Subjects are not on stress ulcer medications including PPIs, H2RBs, and mucosal protectors at 24 h of admission.

06

What researchers measure

Primary outcomes

  1. 90-day mortality after onset

    Proportion of enrolled patients who died 90 days after onset of disease.

    Time frame: 90-day after onset

  2. Incidence of stroke-associated pneumonia

    Incidence of non-mechanically ventilated stroke patients with new pneumonia within 7-day of onset

    Time frame: within 7-day of onset

Secondary outcomes

  1. Incidence of clinically significant bleeding

    One of the following 4 symptoms occurs within 24 hours of bleeding from a stress ulcer (in the absence of other causes):1. A decrease of ≥ 20 mmHg in any one of systolic, diastolic and mean arterial pressure. 2.Initiation of blood pressure boosters or 20% increase in medication dose.3. Decreased hemoglobin ≥ 2 g/d((1.24 mmol/l). 4.Infusion of erythrocytes ≥ 2 U.

    Time frame: within 7-day of onset

  2. Incidence of stress ulcer bleeding

    Coffee-like residue/black stool/blood in stool within 7-day after onset and more than 2 consecutive positive fecal/gastric fluid occult blood

    Time frame: 7-day after onset

  3. Incidence of unfavorable functional prognosis at 90 days after onset

    Incidence of unfavorable functional prognosis at 90 days after onset

    Time frame: 90-day after onset

  4. 90-day mRS score change

    Modified Rankin Scale score change within 90 days after onset in patients who were eligible for inclusion criteria

    Time frame: 90-day after onset

  5. Incidence of early neurological deterioration

    Increased score of National Institutes of Health Stroke Scale within 72h after onset ≥ 4

    Time frame: within 72 hours after onset

  6. 1-year post-onset mortality

    Mortality at 1 year after onset in patients who were eligible for inclusion criteria

    Time frame: 1 year after onset

  7. Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset

    Incidence of adverse related events such as pneumonia or myocardial ischemia 1 year after onset in patients who were eligible for inclusion criteria

    Time frame: 1 year after onset

07

Study locations

19 of 19 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2023 to primary completion in Aug 2026, 39 months.

Of 401 non-industry observational studies under Ischemic Stroke, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 140. This study's 39 months is below that.

Counting every sponsor, half of 443 studies reached it within 53 months; a quarter within 24 and three quarters within 127.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Jan 2027 → Aug 2026 and completion Jan 2027 → May 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 26, 2023
First posted
May 6, 2023
StartActual
May 1, 2023
Primary completionActual
Aug 1, 2026was Jan 2027
CompletionEst.
May 1, 2027was Jan 2027
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 5, 2026
Sites
19 sites changed recruiting status (19 now recruiting)
Show 19 sites
  • Fujian Medical University Union Hospital · Fuzhou, Chinano status→Recruiting
  • Dongguan donghua hospital · Dongguan, Chinano status→Recruiting
  • Dongguan People's Hospital · Dongguan, Chinano status→Recruiting
  • Guangdong Provincial Hospital of Traditional Chinese Medicine · Guangzhou, Chinano status→Recruiting
  • Huadu District People's Hospital of Guangzhou · Guangzhou, Chinano status→Recruiting
  • Nanfang Hospital of Southern Medical University · Guangzhou, Chinano status→Recruiting
  • The Fourth Affiliated Hospital of Guangzhou Medical University · Guangzhou, Chinano status→Recruiting
  • Heyuan people's Hospital · Heyuan, Chinano status→Recruiting
  • Huizhou Municipal Central Hospital · Huizhou, Chinano status→Recruiting
  • Haikou People's Hospital · Haikou, Chinano status→Recruiting
  • Hainan Provincial People's Hospital · Haikou, Chinano status→Recruiting
  • Hainan Traditional Chinese Medicine Hospital · Haikou, Chinano status→Recruiting
  • The First Hospital of Changsha · Changsha, Chinano status→Recruiting
  • The Second Hospital University of South China · Hengyang, Chinano status→Recruiting
  • Yueyang People's Hospital · Yueyang, Chinano status→Recruiting
  • Sinopharm North Hospital · Baotou, Chinano status→Recruiting
  • The Affiliated Hospital of Inner Mongolia Medical University · Hohhot, Chinano status→Recruiting
  • Ganzhou City People's Hospital · Ganzhou, Chinano status→Recruiting
  • Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Chinano status→Recruiting
Nov 5, 2026
Primary completion
Jan 1, 2027→Aug 1, 2026 (actual)
Nov 5, 2026
Study completion
Jan 1, 2027→May 1, 2027
Nov 5, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • The Fourth Affiliated Hospital of Guangzhou Medical University · Guangzhou, ChinaContact added •••5142
Nov 5, 2026
Sponsor
Collaborators added: Guangzhou Medical University·Heyuan Shenhe People's Hospital; collaborators removed: The Fourth Affiliated Hospital of Guangzhou Medical University·Dongguan donghua hospital·Heyuan people's Hospital
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Not yet recruiting→Recruiting
    19 sites changed recruiting status (19 now recruiting)
    Show 19 sites
    • Fujian Medical University Union Hospital · Fuzhou, Chinano status→Recruiting
    • Dongguan donghua hospital · Dongguan, Chinano status→Recruiting
    • Dongguan People's Hospital · Dongguan, Chinano status→Recruiting
    • Guangdong Provincial Hospital of Traditional Chinese Medicine · Guangzhou, Chinano status→Recruiting
    • Huadu District People's Hospital of Guangzhou · Guangzhou, Chinano status→Recruiting
    • Nanfang Hospital of Southern Medical University · Guangzhou, Chinano status→Recruiting
    • The Fourth Affiliated Hospital of Guangzhou Medical University · Guangzhou, Chinano status→Recruiting
    • Heyuan people's Hospital · Heyuan, Chinano status→Recruiting
    • Huizhou Municipal Central Hospital · Huizhou, Chinano status→Recruiting
    • Haikou People's Hospital · Haikou, Chinano status→Recruiting
    • Hainan Provincial People's Hospital · Haikou, Chinano status→Recruiting
    • Hainan Traditional Chinese Medicine Hospital · Haikou, Chinano status→Recruiting
    • The First Hospital of Changsha · Changsha, Chinano status→Recruiting
    • The Second Hospital University of South China · Hengyang, Chinano status→Recruiting
    • Yueyang People's Hospital · Yueyang, Chinano status→Recruiting
    • Sinopharm North Hospital · Baotou, Chinano status→Recruiting
    • The Affiliated Hospital of Inner Mongolia Medical University · Hohhot, Chinano status→Recruiting
    • Ganzhou City People's Hospital · Ganzhou, Chinano status→Recruiting
    • Second Affiliated Hospital of Wenzhou Medical University · Wenzhou, Chinano status→Recruiting
    Primary completion Jan 1, 2027→Aug 1, 2026 (now actual)
    Study completion Jan 1, 2027→May 1, 2027
    Sponsor Collaborators added: Guangzhou Medical University·Heyuan Shenhe People's Hospital; collaborators removed: The Fourth Affiliated Hospital of Guangzhou Medical University·Dongguan donghua hospital·Heyuan people's Hospital
    Site contacts Changed at 1 site. See the sites
    Show the site
    • The Fourth Affiliated Hospital of Guangzhou Medical University · Guangzhou, ChinaContact added •••5142
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05845372
Collaborators
Guangzhou Medical University, The Affiliated Hospital of Inner Mongolia Medical University, Second Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Guangxi Medical University, Fujian Medical University Union Hospital, Huizhou Municipal Central Hospital, Haikou People's Hospital, Kashgar 1st People's Hospital, Ganzhou City People's Hospital, Guangdong Provincial Hospital of Traditional Chinese Medicine, Huadu District People's Hospital of Guangzhou, Dongguan People's Hospital, Sinopharm North Hospital, Heyuan Shenhe People's Hospital, Hainan People's Hospital, Hainan Traditional Chinese Medicine Hospital, The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine, The Second Hospital University of South China, Yueyang People's Hospital
Responsible party
Sponsor
First posted
May 6, 2023
Start date
May 1, 2023
Primary completion
Aug 1, 2026
Completion
May 1, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Suyue Pan, M.D., Ph.D.
Contact
pansuyue@smu.edu.cn
13556184981
Suyue Pan
principal investigator · Department of Neurology, Nanfang Hospital,Southern Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion